


Amendments to the Claims

The following listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (previously presented) A compound of Formula IA:



wherein:

A¹ is aryl or heteroaryl and x is 0, 1, 2, 3, 4 or 5;

either B¹ is aryl and y is 1, 2, 3, 4 or 5, or B¹ is heteroaryl and y is 0, 1, 2, 3, 4 or 5;

provided that x does not exceed the number of substitutable positions of the ring to which each R^a is attached; and y does not exceed number of substitutable positions of the ring to which each R^b is attached;

n is 1;

R¹ is -H, -(C₁-C₈)hydrocarbyl, -CN, -CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;

the configuration of the substituents on the carbon-carbon double bond is either *E*- or *Z*-;

the configuration of the substituents on the sulfoxide sulfur atom is R-, S- or any mixture of R- and S-;

each R^a is independently selected from the group consisting of halogen; -(C₁-C₈)hydrocarbyl, -C(=O)R², -NR²₂, -NHC(=O)R³, -NHSO₂R³, -NHR⁴, -NHCR²R⁴C(=O)R⁶, -C(=O)OR², -C(=O)NHR²; -NO₂, -CN, -OR², -P(=O)(OH)₂,

dimethylamino(C₂-C₆ alkoxy), -NHC(=NH)NHR², -(C₁-C₆)haloalkyl, -(C₁-C₆)haloalkoxy and -N=CH-R⁷;

each R^b attached to aryl is independently selected from the group consisting of -C(=O)R², halogen, -NO₂, -CN, -OR², -C(=O)OR², -NR²₂, (C₁-C₆)haloalkyl and (C₁-C₆)haloalkoxy;

each R^b attached to heteroaryl is independently selected from the group consisting of -(C₁-C₈)hydrocarbyl, -C(=O)R², halogen, -NO₂, -CN, -OR², -C(=O)OR², -NR²₂, (C₁-C₆)haloalkyl and (C₁-C₆)haloalkoxy;

each R² is independently selected from the group consisting of -H and -(C₁-C₈)hydrocarbyl;

each R³ is independently selected from the group consisting of -H, -(C₁-C₈)hydrocarbyl, -O(C₁-C₈)hydrocarbyl, substituted and unsubstituted aryl, substituted heterocyclyl(C₁-C₃)alkyl, heteroaryl(C₁-C₃)alkyl, -(C₂-C₁₀)heteroalkyl, -(C₁-C₆)haloalkyl, -CR²R⁴NHR⁵, -N(R²)₂, -(C₁-C₃)alkyleneNH₂, -(C₁-C₃)alkylene-N(CH₃)₂, -(C₁-C₃)perfluoroalkylene-N(CH₃)₂, -(C₁-C₃)alkylene-N⁺((C₁-C₃)alkyl)₃, -(C₁-C₃)alkylene-N⁺(CH₂CH₂OH)₃, -(C₁-C₃)alkylene-OR², -(C₁-C₄)alkylene-CO₂R², -(C₁-C₄)alkylene-C(=O)halogen, halo(C₁-C₃)alkyl-, -(C₁-C₃)alkylene-C(=O)(C₁-C₃)alkyl, and -(C₁-C₄)perfluoroalkylene-CO₂R²;

each R⁴ is independently selected from the group consisting of -H, -(C₁-C₆)alkyl, -(CH₂)₃-NH-C(NH₂)(=NH), -CH₂C(=O)NH₂, -CH₂COOH, -CH₂SH, -(CH₂)₂C(=O)-NH₂, -(CH₂)₂COOH, -CH₂-(2-imidazolyl), -(CH₂)₄-NH₂, -(CH₂)₂-S-CH₃, phenyl, -CH₂-phenyl, -CH₂-OH, -CH(OH)-CH₃, -CH₂-(3-indolyl), and -CH₂-(4-hydroxyphenyl);

each R⁵ is independently selected from the group consisting of -H and a carboxy terminally linked peptidyl residue containing from 1 to 3 amino acids in which the terminal amino group of the peptidyl residue is present as a functional group selected from the group consisting of -NH₂ and -NHC(=O)(C₁-C₆)alkyl, -NH(C₁-C₆)alkyl, -N(C₁-C₆alkyl)₂ and -NHC(=O)O(C₁-C₇)hydrocarbyl;


each R⁶ is independently selected from the group consisting of -OR² and an *N*-terminally linked peptidyl residue containing from 1 to 3 amino acids in which the

terminal carboxyl group of the peptidyl residue is present as a functional group selected from the group consisting of $-\text{CO}_2\text{R}^2$ and $-\text{C}(=\text{O})\text{NR}^2_2$; and

each R^7 is independently selected from the group consisting of substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl;


* indicates that, when R^1 is other than $-\text{H}$, the configuration of the substituents on the designated carbon atom is R-, S- or any mixture of R- and S-; or a salt of such a compound.

2. (previously presented) A compound according to claim 1 of Formula IAz:



or a salt thereof.


3. (previously presented) A compound according to claim 1 of the Formula IAe:



or a salt thereof.


4. (canceled)

5. (previously presented) A compound according to claim 1, or a salt thereof, wherein the sum of x and y is greater than zero.
6. (previously presented) A compound according to claim 5, or a salt thereof, wherein A¹ is an aryl radical.
7. (previously presented) A compound according to claim 6 selected from the group consisting of: (1E)-2-(4-fluorophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(4-chlorophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(4-bromophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(2-nitrophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; (1E)-2-(3-nitrophenyl)-1-[(naphthylmethyl)sulfinyl]ethene; and (1E)-2-(4-nitrophenyl)-1-[(naphthylmethyl)sulfinyl]ethene.
8. (previously presented) A compound according to claim 6, of Formula IB:



or a salt thereof.

9. (previously presented) A compound according to claim 8, or a salt thereof, wherein each R^a is independently selected from the group consisting of halogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, -NO₂, -CN, -C(=O)OR², -OH, -NH₂, (C₁-C₆)trifluoroalkoxy and -CF₃.
10. (previously presented) A compound according to claim 8, of Formula IC:



or a salt thereof.

11. (previously presented) A compound according to claim 10 wherein each R^a is independently selected from the group consisting of halogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, -NO₂, -CN and -CF₃, and each R^b is independently selected from the group consisting of halogen, (C₁-C₆)alkoxy, -NO₂, -CN and -CF₃.
12. (previously presented) A compound according to claim 10, or a salt thereof, wherein the configuration of the substituents on the carbon-carbon double bond is *E*-.
13. (previously presented) A compound according to claim 12, or a salt thereof, wherein x is 0, 1 or 2 and y is 1 or 2.
14. (previously presented) A compound according to claim 12 selected from the group consisting of: (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl) ethene; (1E)-1-{[(3-hydroxy-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl) ethene; (1E)-1-{[(4-methoxy-3-nitrophenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl) ethene; 2-({[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]amino}sulfonyl)acetic acid; 2-{N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}acetic acid; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]aminocarboxamidine; 2-{[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]amino}acetic acid; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](3,5-dinitrophenyl)carboxamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](3,5-diaminophenyl)carboxamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-chloroacetamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(4-methylpiperazinyl)acetamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]benzamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl](4-nitrophenyl)carboxamide; N-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](4-

aminophenyl)carboxamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)-vinyl]sulfinyl}methyl)-2-methoxyphenyl](2R)-2,6-diaminohexanamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](2R)-2-amino-3-hydroxypropanamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl](2S)-2-amino-3-hydroxypropanamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]aminamide; (1E)-1-({[4-methoxy-3-(methylamino)phenyl]methyl}sulfinyl)-2-(2,4,6-trimethoxyphenyl)ethene; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]acetamide; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(2,4-dinitrophenyl)sulfonyl]amine; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(2,4-diaminophenyl)sulfonyl]amine; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(dimethylamino)-acetamide; 2-{[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]amino}propanoic acid; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][4-(4-methylpiperazinyl)phenyl]carboxamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-hydroxyacetamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-pyridylacetamide; {*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}methyl acetate; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-hydroxypropanamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-(triethylamino)acetamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-[tris(2-hydroxyethyl)amino]acetamide; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2-hydroxy-2-methylpropanamide; 1-{*N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]carbamoyl}-isopropyl acetate; *N*-[5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl]-2,2,2-trifluoroacetamide; [5-({[(1E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}methyl)-2-methoxyphenyl][(trifluoro-

methyl)sulfonyl]amine; 3-{*N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]-sulfinyl)methyl]-2-methoxyphenyl]carbamoyl}propanoic acid; 3-{*N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}propanoyl chloride; 3-({*N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}methyloxycarbonyl}propanoic acid; 4-{*N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}butanoic acid; *N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl)methyl]-2-methoxyphenyl]-2-(phosphonooxy)acetamide, disodium salt; 4-{[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl)methyl]-2-methoxyphenyl]amino}butanoic acid; 3-{[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl)methyl]-2-methoxyphenyl]amino}propanoic acid; *N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl)methyl]-2-methoxyphenyl]methoxycarboxamide; [5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl)methyl]-2-methoxyphenyl][(4-methoxyphenyl)sulfonyl]amine; {*N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl)methyl]-2-methoxyphenyl]carbamoyl}ethyl acetate; methyl-3-{*N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]-sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}propanoate; ethyl-2-{*N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}acetate; *N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl)methyl]-2-methoxyphenyl]-2,2,3,3,3-pentafluoropropanamide; methyl-2-{*N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]-sulfinyl)methyl]-2-methoxyphenyl]carbamoyl}-2,2-difluoroacetate; 3-{*N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}-2,2,3,3-tetrafluoropropanoic acid; *N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl)methyl]-2-methoxyphenyl]-2-aminoacetamide; 2-{*N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl}-methyl)-2-methoxyphenyl]carbamoyl}-2,2-difluoroacetic acid; *N*-[5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfinyl)methyl]-2-methoxyphenyl]-2-(dimethylamino)-2,2-difluoroacetamide, 4-((1*E*)-2-{[(4-fluorophenyl)methyl]sulfinyl}vinyl)benzoic acid; 4-((1*E*)-2-{[(4-iodophenyl)methyl]sulfinyl}vinyl)benzoic acid; 4-((1*E*)-2-{[(4-chlorophenyl)methyl]sulfinyl}vinyl)benzoic acid;

acid; 1-[5-((1E)-2-[[4-(chlorophenyl)methyl]sulfinyl]vinyl)-2-fluoro-phenyl]-2-(dimethylamino)ethan-1-one; (1E)-2-(2,4-difluorophenyl)-1-[[4-(bromophenyl)methyl]sulfinyl]ethene; (1E)-2-(3-amino-4-fluorophenyl)-1-[[4-(chlorophenyl)methyl]sulfinyl]ethene; (1E)-1-[[4-(fluorophenyl)methyl]sulfinyl]-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-[[4-(chlorophenyl)methyl]sulfinyl]-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-[[4-(bromophenyl)methyl]sulfinyl]-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-2-(4-fluorophenyl)-1-[[2,3,4,5,6-pentafluorophenyl)methyl]sulfinyl]ethene; (1E)-2-(4-chlorophenyl)-1-[[2,3,4,5,6-pentafluorophenyl)methyl]sulfinyl]ethene; (1E)-2-(4-bromophenyl)-1-[[2,3,4,5,6-pentafluorophenyl)methyl]sulfinyl]ethene; (1E)-1-[[3,4-dichlorophenyl)methyl]sulfinyl]-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-[[4-(iodophenyl)methyl]sulfinyl]-2-(2,3,4,5,6-pentafluorophenyl)ethene; (1E)-1-[[4-(fluorophenyl)methyl]sulfinyl]-2-(2-hydroxy-3,5-dinitrophenyl)ethene; (1E)-1-[[4-(bromophenyl)methyl]sulfinyl]-2-(2-hydroxy-3,5-dinitrophenyl)ethene; (1E)-1-[[4-(chlorophenyl)methyl]sulfinyl]-2-(2-hydroxy-3,5-dinitrophenyl)ethene; (1E)-1-[[2,4-dichlorophenyl)methyl]sulfinyl]-2-(2-hydroxy-3,5-dinitrophenyl)ethene; (1E)-1-[[4-(methoxyphenyl)methyl]sulfinyl]-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-[[4-(methoxyphenyl)methyl]sulfinyl]-2-(3,4,5-trimethoxyphenyl)ethene; (1E)-1-[[2-nitro-4,5-dimethoxyphenyl)methyl]sulfinyl]-2-(3,4,5-trimethoxyphenyl)ethene; (1E)-1-[[2-nitro-4,5-dimethoxyphenyl)methyl]sulfinyl]-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-[[4-(fluorophenyl)methyl]sulfinyl]-2-(2,3,4-trifluorophenyl)ethene; (1E)-1-[[4-(chlorophenyl)methyl]sulfinyl]-2-(2,3,4-trifluorophenyl)ethene; (1E)-1-[[4-(methoxyphenyl)methyl]sulfinyl]-2-(2,6-methoxy-4-hydroxyphenyl)ethene; (1E)-1-[[4-(methoxyphenyl)methyl]sulfinyl]-2-(2,3,5,6-tetrafluorophenyl)ethene; (1E)-1-[[4-(methoxyphenyl)methyl]sulfinyl]-2-(2,4,5-trimethoxyphenyl)ethene; (1E)-1-[[4-(methoxyphenyl)methyl]sulfinyl]-2-(2,3,4-trimethoxyphenyl)ethene; (1E)-1-[[4-(methoxyphenyl)methyl]sulfinyl]-2-(3-nitro-4-hydroxy-5-methoxyphenyl)ethene; (1E)-1-[[4-(methoxyphenyl)methyl]sulfinyl]-2-(3,4-dimethoxy-6-nitrophenyl)ethene; (1E)-1-[[4-(methoxyphenyl)methyl]sulfinyl]-2-(3,4-dimethoxy-5-iodophenyl)ethene; (1E)-1-[[4-(methoxyphenyl)methyl]sulfinyl]-2-(2,6-

dimethoxy-4-fluorophenyl)ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(2-hydroxy-4,6-dimethoxyphenyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2,6-dimethoxy-4-fluorophenyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2-hydroxy-4,6-dimethoxyphenyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2,6-dimethoxy-4-fluorophenyl)ethene; (1E)-1-{[(2,4,6-trimethoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-{[(2,3,4-trimethoxyphenyl)methyl]sulfinyl}-2-(2,6-dimethoxyphenyl)ethene; (1E)-1-{[(3,4,5-trimethoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; (1E)-1-{[(3,4,5-trimethoxyphenyl)methyl]sulfinyl}-2-(2,6-dimethoxyphenyl)ethene; (1E)-1-{[(3,4,5-trimethoxyphenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-2-(4-fluorophenyl)-1-([4-(trifluoromethyl)phenyl]methyl)sulfinyl)ethene; (1E)-2-(4-chlorophenyl)-1-([4-(trifluoromethyl)phenyl]methyl)sulfinyl)ethene; (1E)-2-(4-bromophenyl)-1-([4-(trifluoromethyl)phenyl]methyl)sulfinyl)ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(4-chlorophenyl)ethene; (1E)-1-{[(3,4-dichlorophenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-1-{[(3,4-dichlorophenyl)methyl]sulfinyl}-2-(4-chlorophenyl)ethene; (1E)-1-{[(3,4-dichlorophenyl)methyl]sulfinyl}-2-(4-bromophenyl)ethene; (1E)-2-(4-fluorophenyl)-1-([4-nitrophenyl]methyl)sulfinyl)ethene; 4-([[(1E)-2-(4-fluorophenyl)vinyl]sulfinyl]methyl)benzene-carbonitrile; 4-([[(1E)-2-(4-chlorophenyl)vinyl]sulfinyl]methyl)benzene-carbonitrile; 4-([[(1E)-2-(4-bromophenyl)vinyl]sulfinyl]methyl)benzene-carbonitrile; (1E)-2-(3,4-difluorophenyl)-1-([4-(chlorophenyl)methyl]sulfinyl)ethene; (1E)-2-(3-chloro-4-fluorophenyl)-1-([4-(chlorophenyl)methyl]sulfinyl)ethene; (1E)-2-(2-chloro-4-fluorophenyl)-1-([4-(chlorophenyl)methyl]sulfinyl)ethene; (1E)-2-(2,4-dichlorophenyl)-1-([4-(chlorophenyl)methyl]sulfinyl)ethene; (1E)-2-(3,4-dichlorophenyl)-1-([4-(chlorophenyl)methyl]sulfinyl)ethene; (1E)-2-(2,3-dichlorophenyl)-1-([4-(chlorophenyl)methyl]sulfinyl)ethene; (1E)-2-(4-fluorophenyl)-1-([4-(iodophenyl)methyl]sulfinyl)ethene;

(1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(4-iodophenyl)-ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(4-iodophenyl)-ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-iodophenyl)-ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-chlorophenyl)-ethene; (1E)-2-(4-bromophenyl)-1-{[(4-iodophenyl)methyl]sulfinyl}ethene; (1E)-1-{[(4-iodophenyl)methyl]sulfinyl}-2-(4-nitrophenyl)-ethene; (1E)-1-{[(4-iodophenyl)methyl]sulfinyl}-2-(2-nitrophenyl)-ethene; (1E)-2-(4-iodophenyl)-1-{[(4-methoxyphenyl)methyl]sulfinyl}ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(4-iodophenyl)-ethene; (1E)-2-(3,4-dichlorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-trifluoromethylphenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-trifluoromethylphenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-trifluoromethylphenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-trifluoromethyl-4-fluorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-trifluoromethylphenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-trifluoromethylphenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-trifluoromethylphenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-trifluoromethyl-4-fluorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-trifluoromethyl-4-fluorophenyl)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-nitrophenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-nitrophenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-nitrophenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(2-trifluoromethylphenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(3-trifluoromethylphenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-trifluoromethylphenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene;

15. (previously presented) A compound according to claim 10 wherein:

x is 0 or 1;


y is 1, 2 or 3.

- 12 -

17. (previously presented) A compound according to claim 16 selected from the group consisting of: (1E)-2-(2-chlorophenyl)-1-[benzylsulfinyl]ethene; (1E)-2-(4-chlorophenyl)-1-[benzylsulfinyl]ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-2-(4-chlorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}-ethene; (1E)-2-(4-fluorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(2,4-difluorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-fluorophenyl)ethene; (1E)-2-(4-bromophenyl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; (1E)-2-(4-bromophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; and (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-chlorophenyl)ethene.
18. (previously presented) A compound according to claim 10, wherein:
each R^a is independently selected from the group consisting of halogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, -NO₂, -CN and -CF₃, and each R^b is independently selected from the group consisting of (C₁-C₆)alkoxy, halogen and nitro, and is bonded to the ortho or para position of the ring to which it is attached;
x is 0, 1, 2 or 3; and
y is 1, 2 or 3.
19. (previously presented) A compound according to claim 18, wherein the configuration of the substituents on the carbon-carbon double bond is Z-.
20. (previously presented) A compound according to claim 19 selected from the group consisting of: (1Z)-2-(4-chlorophenyl)-1-[benzylsulfinyl]ethene; (1Z)-2-(4-chlorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}-ethene; (1Z)-2-(4-chlorophenyl)-1-{[(2-chlorophenyl)methyl]sulfinyl}-ethene; (1Z)-2-(4-chlorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-fluorophenyl)-1-[benzylsulfinyl]ethene; (1Z)-2-(4-fluorophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-fluorophenyl)-1-{[(2-chlorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-fluorophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-bromophenyl)-1-[benzylsulfinyl]ethene;

(1Z)-2-(4-bromophenyl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-bromophenyl)-1-{[(2-chlorophenyl)methyl]sulfinyl}ethene; (1Z)-2-(4-bromophenyl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; and (1Z)-2-(4-fluorophenyl)-1-{[(4-iodophenyl)methyl]sulfinyl}ethene.

21. (previously presented) A compound according to claim 5, of Formula ID:



wherein B² is selected from the group consisting of heteroaryl and aryl other than phenyl
or a salt thereof.

22. (previously presented) A compound according to claim 21, or a salt thereof, wherein B² is heteroaryl.
23. (previously presented) A compound according to claim 21, or a salt thereof, wherein B² is selected from the group consisting of furyl, thienyl, pyrrolyl, thiazolyl, pyridyl, thienyl-1,1-dioxide, anthryl, and naphthyl.
24. (previously presented) A compound according to claim 23, or a salt thereof, wherein the configuration of the substituents on the carbon-carbon double bond is *E*-.
25. (previously presented) A compound according to claim 24, or a salt thereof, wherein R^a is independently selected from the group consisting of halogen, (C₁-C₃)alkoxy, -CN, -NO₂, and -CF₃.
26. (original) A compound of claim 25 selected from the group consisting of: (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(2-pyridyl)ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(3-pyridyl)ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(4-

pyridyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2-pyridyl)ethene; (1E)-1-
 {[(4-chlorophenyl)methyl]sulfinyl}-2-(3-pyridyl)ethene; (1E)-1-{[(4-
 chlorophenyl)methyl]sulfinyl}-2-(4-pyridyl)ethene; (1E)-1-{[(4-
 bromophenyl)methyl]sulfinyl}-2-(2-pyridyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]-
 sulfinyl}-2-(3-pyridyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(4-
 pyridyl)ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(2-thienyl)ethene; (1E)-1-
 {[(4-chlorophenyl)methyl]sulfinyl}-2-(2-thienyl)ethene; (1E)-1-{[(4-
 bromophenyl)methyl]sulfinyl}-2-(2-thienyl)ethene; (1E)-2-(4-bromo(2-thienyl))-1-{[(4-
 fluorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(5-bromo(2-thienyl))-1-{[(4-
 fluorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(5-bromo(2-thienyl))-1-{[(4-
 chlorophenyl)methyl]-sulfinyl}ethene; (1E)-2-(5-bromo(2-thienyl))-1-{[(4-
 bromophenyl)methyl]-sulfinyl}ethene; 2-((1E)-2-{[(4-
 fluorophenyl)methyl]sulfinyl}vinyl)thiole-1,1-dione; 2-((1E)-2-{[(4-chlorophenyl)-
 methyl]sulfinyl}vinyl)thiole-1,1-dione; 2-((1E)-2-{[(4-bromophenyl)methyl]-
 sulfinyl}vinyl)thiole-1,1-dione; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(3-
 thienyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-
 {[(4-bromophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-
 iodophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-
 methylphenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-methoxyphenyl)-
 methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-trifluoromethylphenyl)methyl]-
 sulfinyl}-2-(3-thienyl)-ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(3-
 thienyl)-ethene; (1E)-1-{[(3,4-dichlorophenyl)methyl]sulfinyl}-2-(3-thienyl)-ethene;
 (1E)-1-{[(4-cyanophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; (1E)-1-{[(4-
 nitrophenyl)methyl]sulfinyl}-2-(3-thienyl)ethene; 3-((1E)-2-{[(4-
 fluorophenyl)methyl]sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{[(4-
 chlorophenyl)methyl]sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{[(4-bromophenyl)-
 methyl]sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{[(4-methoxyphenyl)-
 methyl]sulfinyl}vinyl)thiole-1,1-dione; 3-((1E)-2-{[(2,4-dichlorophenyl)methyl]-
 sulfinyl}vinyl)thiole-1,1-dione; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(2-

furyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2-furyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2-furyl)ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-iodophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-methylphenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-trifluoromethylphenyl)methyl]sulfinyl}-2-(3-furyl)-ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(3,4-dichlorophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-cyanophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-nitrophenyl)methyl]sulfinyl}-2-(3-furyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(1,3-thiazol-2-yl)-ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-pyrrol-2-ylethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-pyrrol-2-ylethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{[(4-iodophenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{[(2,4-dichlorophenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{[(4-methoxyphenyl)methyl]sulfinyl}-2-(5-nitro(3-thienyl))ethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-naphthylethene; (1E)-1-{[(4-fluorophenyl)methyl]sulfinyl}-2-(2-naphthyl)ethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-naphthylethene; (1E)-1-{[(4-chlorophenyl)methyl]sulfinyl}-2-(2-naphthyl)ethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-naphthylethene; (1E)-1-{[(4-bromophenyl)methyl]sulfinyl}-2-(2-naphthyl)ethene; (1E)-2-(9-anthryl)-1-{[(4-fluorophenyl)methyl]sulfinyl}ethene; (1E)-2-(9-anthryl)-1-{[(4-chlorophenyl)methyl]sulfinyl}ethene; (1E)-2-(9-anthryl)-1-{[(4-bromophenyl)methyl]sulfinyl}ethene; and salts thereof.

27. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

28. (previously presented) A conjugate of the Formula, IC-L-Ab;
wherein:
IC is a compound according to claim 10 or a pharmaceutically acceptable salt thereof;
Ab is an antibody; and
-L- is a single covalent bond or a linking group covalently linking said compound to said antibody.
29. (original) A conjugate according to claim 28 wherein said antibody Ab is a monoclonal antibody or a monospecific polyclonal antibody.
30. (original) A conjugate according to claim 29 wherein said antibody Ab is a tumor-specific antibody.
31. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one conjugate according to claim 28.
32. (previously presented) A method of treating an individual for breast cancer, prostate cancer, lung cancer or colorectal cancer comprising administering to said individual in need of such treatment an effective amount of a compound according to claim 10, or a pharmaceutically acceptable salt thereof.
33. (canceled)
34. (canceled)
35. (canceled)
36. (previously presented) A method of treating an individual for a cancer selected from the group consisting of breast, prostate, lung, and colorectal cancers, comprising administering to said individual an effective amount of a compound according to claim

- 10, or a pharmaceutically acceptable salt thereof, and administering an effective amount of therapeutic ionizing radiation to the individual.
37. (previously presented) A method of inducing apoptosis of tumor cells in an individual afflicted with breast cancer, prostate cancer, lung cancer or colorectal cancer comprising administering to said individual an effective amount of a compound according to claim 10, or a pharmaceutically acceptable salt thereof.
38. (canceled)
39. (previously presented) A method of treating an individual afflicted with breast cancer, prostate cancer, lung cancer or colorectal cancer, comprising administering to said individual an effective amount of at least one conjugate according to claim 28.
40. (canceled)
41. (canceled)
42. (canceled)
43. (canceled)
44. (canceled)
45. (canceled)
46. (canceled)
47. (canceled)
48. (canceled)
49. (canceled)

50. (canceled)

51. (canceled)

52. (canceled)

53. (canceled)

54. (canceled)

55. (canceled)

56. (canceled)

57. (canceled)

58. (canceled)

59. (canceled)

60. (canceled)

61. (canceled)

62. (canceled)

63. (canceled)

64. (canceled)


65. (canceled)

66. (canceled)

67. (canceled)

68. (canceled)

69. (currently amended) A process for preparing a compound according to claim 3 of Formula Ie:



wherein:

A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

B is substituted aryl or substituted or unsubstituted heteroaryl;


n is 1;


R¹ is H, (C₁-C₈)hydrocarbyl, CN, CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;

the configuration of the substituents on the sulfoxide sulfur atom is R, S or any mixture of R and S;


* indicates that, when R¹ is other than H, the configuration of the substituents on the designated carbon atom is R, S or any mixture of R and S; or a salt of such a compound, comprising:

(a) reacting a compound of Formula H II':






~~R¹ is H, (C₁-C₈)hydrocarbyl, CN, CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;~~
with a compound of Formula III III':



70. (currently amended) A process according to claim 69 wherein the compound of Formula **II'** is prepared by[[:]];:

- 21 -




with an oxidizing agent capable of oxidizing a sulfide to a sulfoxide; and

(b) isolating a compound of Formula H II' from the reaction products.

71. (currently amended) A process according to claim 70 wherein the compound of Formula ~~HA~~ IIA' is prepared by:

(a) reacting a compound of Formula ~~HB~~ IIB':




wherein:

L is a leaving group;

with mercaptoacetic acid; and

(b) isolating a compound of Formula HA IIA' from the reaction products.

72. (currently amended) A process for preparing a compound according to claim 2 of Formula Iz:



wherein:

~~A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;~~

~~B is substituted aryl or substituted or unsubstituted heteroaryl;~~


~~n is 1;~~


~~R¹ is H, (C₁-C₈)hydrocarbyl, CN, CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;~~

~~the configuration of the substituents on the sulfoxide sulfur atom is R, S or any mixture of R and S;~~

~~* indicates that, when R¹ is other than H, the configuration of the substituents on the designated carbon atom is R, S or any mixture of R and S; or a salt of such a compound, comprising:~~

(a) reacting a compound of Formula IV IV':





wherein A^1 , B^1 , n , R^1 , R^a , R^b , x and y are defined as in claim 1 :

~~A is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;~~

~~B is substituted aryl or substituted or unsubstituted heteroaryl;~~

~~n is 1; and~~


~~R^1 is H, (C₁-C₈)hydrocarbyl, CN, CO₂(C₁-C₆)alkyl or halo(C₁-C₆)alkyl;~~

~~with an oxidizing agent capable of oxidizing a sulfide to a sulfoxide; and~~

~~(b) isolating a compound of claim 2 Formula I~~z~~ from the reaction products.~~


73. (currently amended) A process according to claim 72 wherein the compound of Formula ~~IV~~ IV' is prepared by:

(a) reacting a compound of Formula ~~IVA~~ IVA':



wherein Q^+ is a counterion selected from the group consisting of alkali metals, alkaline earth metals and transition metals;

with a compound of Formula ~~IVB~~ IVB':



(b) isolating a compound of Formula ~~IV~~ IV' from the reaction products.

74. (canceled)
75. (canceled)
76. (canceled)
77. (previously presented) An isolated optical isomer of a compound according to claim 1, or a salt thereof.